Isogenica is a UK biotechnology company that develops and licenses discovery technologies for antibodies and related biologics. It designs synthetic antibody libraries and display systems, including single-domain and human antibody fragment libraries, to enable antibody discovery and development. The company also provides peptide and scaffold platforms and supports the construction of multi-specific therapeutics, antibody–drug conjugates, and other targeted delivery approaches. Its CIS display technology enables discovery of biologically active peptides, proteins, and antibodies. Isogenica serves pharmaceutical and biotechnology customers worldwide from bases in the United Kingdom.
Karyon, Ltd. develops peptides into carriers for use in cancer diagnostics, imaging, and therapy. It offers Karyon Targeting Unit, a synthetic peptide that targets specific tumor tissue. The company engages in the areas of cancer biology and cell growth regulation, angiogenesis, biochemistry, peptide chemistry, organic syntheses and immunohistochemistry. Karyon, Ltd. was founded in 2001 and is based in Helsinki, Finland. As of May 6, 2008, Karyon Ltd. operates as a subsidiary of Isogenica Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.